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Introduction 
A young male patient was recently 
admitted to the intensive care unit 
at a local hospital with hypertensive 
urgency and acute renal failure of 
unknown etiology.  A renal 
ultrasound showed polycystic 
kidneys and upon further 
investigation, it was discovered that 
the patient’s mother passed away 
last year from end stage renal 
failure related to polycystic kidney 
disease (PKD).  The aforementioned 
case and the recent study into 
inherited disorders are what 
prompted further investigation into 
PKD.  Liebau and Serra (2013) 
explain that “inherited cystic kidney 
diseases, autosomal dominant 
polycystic kidney disease (ADPKD) 
and autosomal recessive polycystic 
kidney disease (ARPKD), are the 
most common monogenetic causes 
of end-stage renal disease (ESRD) in 
children and adults” (p. 1771).  It is 
estimated that one in a thousand 
individuals will be diagnosed with 
PKD in adulthood and one in twenty 
thousand in childhood (Liu et al, 
2012, p. 1).  Considering this 
statistic, patients with PKD may be 
seen throughout all facets of health 
care.  As a health care provider, 
primary or otherwise, it is 
important to educate and 
appropriately treat PKD patients in 
an effort to prevent unnecessary 
damage to their bodies related to 
complications of the disease.  The 
utilization of genetic testing is not 
standard treatment, but may pose 
some benefits to certain at risk 
patients in identifying the disease.  
However, healthy lifestyle choices 
are necessary in order to slow 
disease progression. 
Pathophysiology 
Eisenberger, et al. (2015) state that 
“renal cysts are clinically and 
genetically heterogeneous 
conditions” (p. 1).  ADPKD is the 
most commonly diagnosed form of 
PKD and is typically diagnosed 
during adulthood; it results from a 
mutation in either of two genes, 
PKD1, which encodes polycystin 1 
(PC1) or PKD2, which encodes 
polycystin 2 (PC2), both of which 
are membrane proteins (Reed-
Gitomer, 2014, p. 17).  Srivastava 
and Patel (2014) explain that 
“mutations of PKD 1 (eight-five 
percent of cases) or PKD 2 (fifteen 
percent of cases) can lead to signal 
dysregulation and increased levels 
of cyclic adenosine 
monophosphate, culminating into 
cytogenesis.  Given the dominant 
nature of transmission, there is at 
least a fifty percent probability that 
a child of an affected parent will 
inherit the disease.  A spontaneous 
mutation causes ADPKD in five 
percent of cases” (p. 303).  It is 
difficult to determine genetic 
mutations for ADPKD early on due 
to the sizes and structures of PKD 1 
and 2.  Since the detection of the 
aforementioned genetic mutations 
can be difficult, genetic testing can 
be costly for patients.  Definitive 
diagnosis of PKD is based on two 
factors, a positive family history and 
an age-specific cystic renal 
phenotype (Bataille, Berland, 
Fontes, & Burtey, 2011, p. 1).  
During genetic testing, DNA linkage 
and gene-based 
sequencing/mapping are utilized for 
the diagnosis of ADPKD (Pei, 2011, 
p. 19).  Once an adult is diagnosed 
with PKD, it is easier to isolate the 
genetic mutation and test younger 
generations for the same 
anomalies.   
ADPKD manifests as fluid-filled 
cystic dilation of renal tubules.  
Chang and Ong (2013) state that 
“cyst initiation and expansion arise 
from a combination of abnormal 
cell proliferation, fluid secretion, 
and extracellular matrix defects and 
results in kidney enlargement and 
interstitial fibrosis” (p. 524).  
Current research suggests that the 
primary reason behind renal cyst 
formation in both ADPKD and 
ARPKD is related to defects in cilia-
mediated signals (Halvorson, 
Bremmer, and Jacobs, 2010).  The 
gene products, polycystin 1 and 2, 
that are affected in ADPKD, regulate 
the growth of the epithelium in the 
renal tubules.  The genetic defects 
associated with PKD affect the 
formation of the epithelial cells and 
the cilium, resulting in the 
formation of cysts.  The presence of 
cilia is found on almost all surfaces 
of nephron cells, which means that 
cysts have the potential to form on 
these areas as well.  In PKD, the 
“function of the primary cilium is 
impaired, resulting in the disruption 
of a number of intracellular 
signaling cascades that produce 
dedifferentiation of cystic 
epithelium, increased cell division, 
increased apoptosis, and loss of 
resorptive capacity” (Halvorson, 
Bremmer, & Jacobs, 2010, p. 73).  As 
cysts form and grow, they compress 
the renal vessels and obstruct their 
flow, this ultimately leads to 
intracellular ischemia and the 
activation of the renin-angiotensin-
aldosterone system (RAAS); which 
will eventually lead to progressive 
cyst growth, renal fibrosis, 
increased systemic vascular 
resistance, and the retention of 
sodium (Halvorson, Bremmer, & 
Jacobs, 2010, p. 74).  The 
destruction of the renal 
parenchyma and the loss of 
functioning nephrons that result 
from this process is irreversible.  
The abnormal function of polycystin 
1 and 2 also plays a role in vascular 
manifestations, due to the fact that 
these gene products may be 
expressed in the vascular 
endothelium and smooth muscle.  
Polycystin 1 and 2 are affiliated with 
a receptor-ion channel complex on 
the membranes of cilia, resulting in 
calcium dependent signals 
(Halvorson, Bremmer, & Jacobs, 













present with defects, intracellular 
calcium homeostasis is affected 
which produces “alterations of 
endothelium-dependent relaxation 
and increased systolic blood 
pressures” (Halvorson, Bremmer, & 
Jacobs, 2010, p. 74). 
Clinical Manifestations 
The enlarging kidneys of PKD 
progress over decades, which leads 
to renal failure in the majority of 
patients by age sixty (Ma, Tian, 
Igarashi, Pazour, & Somlo, 2013, p. 
1004).  Many patients are 
asymptomatic until later in life; 
most are diagnosed between the 
ages of thirty and forty.  The 
gradual loss of nephrons related to 
the formation and increasing size of 
cysts is not usually detectable 
during the first few decades of life. 
(Srivastava & Patel, 2014, p. 303).  
The presentation of the disease 
varies based on the presence of 





















The preferred diagnostic tools are 
imaging studies.  Ultrasonography is 
the preferred method due to its 
cost effectiveness, however 
magnetic resonance imaging (MRI) 
or computed tomography (CT) scans 
are more sensitive.  Once a patient 
is diagnosed, the best option is to 
adopt healthy lifestyle choices in an 
attempt to slow disease progression 
and minimize the risk of developing 
other comorbidities.   
Implications for 
Nursing Practice 
As a primary health care provider it 
is important to obtain a detailed 
family history as well as an in depth 
evaluation of the patient, including 
signs, symptoms, social behaviors, 
diet, etc.  The focus of nursing care 
provided to PKD patients is 
education; key topics include 
exercise, diet, and general 
compliance.  Adequate exercise and 
an appropriate diet are important 
components in almost any disease 
process.  PKD patients should have 
a diet that is low in cholesterol to 
reduce cardiovascular risks, as well 
as lowering the intake of proteins, 
phosphorus, sodium, and 
potassium in an effort to preserve 
renal function and prevent further 
renal injury (Maditz, Gigliotti, & 
Tou, 2013, p. 803).  Primary 
modalities of treatment are related 
to disease-related symptoms, such 
as hypertension and pain.  It is 
extremely important for PKD 
patients to monitor their blood 
pressure frequently and maintain 
medication compliance in regards 
to hypertension, if applicable.  Once 
PKD has progressed to ESRD, 
patients will likely require 
hemodialysis and/or a renal 
transplant.  However, over the last 
few years, a variety of clinical trials 
with regards to slowing the 
progression of PKD have made 
advances in the field (Reed-
Gitomer, 2014, p. 177).  
Conclusion 
In the grand scheme of diseases, 
PKD is considered rare.  However, 
once it is diagnosed the 
complications that can/will result 
from it are life threatening.  PKD is 
frequently misdiagnosed because 
many of the signs and symptoms 
that go along with it are similar to 
other ailments/diseases, such as 
primary hypertension or a typical 
UTI.  Once a patient is diagnosed 
with PKD, he or she must be 
educated on the disease itself, 
complications that may arise, and 
diet recommendations.  Efforts 
must be made to decrease risks to 
the cardiovascular system as well, 
including smoking cessation if 
necessary and adequate exercise 
routines.  If it is determined that the 
patient has ADPKD, it may be 
beneficial to perform gene mapping 
on his or her siblings as well as his 
or her children if applicable.  Renal 
failure is an inevitability in PKD, 
how quickly a patient gets to that 
point is up to him or her and their 
primary care provider. 
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